NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
More attention needed for potential impact of drug waste on drinking water quality Drug waste contains substances that are harmful to the quality of drinking water. Because this waste is dumped illegally, these substances can end up in sources of drinking water.
Key persons should be involved in policy for pandemics RIVM advises government authorities to involve ‘key persons’ in formulating policy for current and future pandemics. Results from RIVM research show that these individuals played a key role in ensuring an ongoing focus on social well-being and mental health during the COVID-19 pandemic, despite the limitations.
Incorrect emission factors used for some farms included in list of top 100 ammonia emitters At the request of the Dutch House of Representatives, RIVM compiled a list of the 100 biggest ammonia emitters in the Netherlands. Recently, the underlying data used to compile this list were disclosed pursuant to a request under the Open Government Act.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
RIVM creates overview of nitrogen monitoring in water in Europe At the behest of the European Parliament, the National Institute for Public Health and the Environment (RIVM) has formulated a report on how EU member states are dealing with European regulations on nitrogen in water (nitrate). Michel Looyenstein
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.